Roivant Sciences (ROIV) Income from Discontinued Operations (2023 - 2024)
Roivant Sciences (ROIV) posted Income from Discontinued Operations of 862000.0 for Q4 2024, down 207.21% on a QoQ basis from 804000.0 in Q3 2024, and down 122.07% year-over-year from 3905000.0 in Q1 2024.
Roivant Sciences (ROIV) Income from Discontinued Operations (2023 - 2024) Analysis & Trends
Roivant Sciences' Income from Discontinued Operations history runs 2 years deep, the most recent figure standing at 862000.0 for Q4 2024.
- Quarterly Income from Discontinued Operations fell 122.07% year-over-year to 862000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 4539000.0 (changed N/A YoY) and the FY2025 annual result came in at 634000.0, down 12.07% from the prior year.
- Income from Discontinued Operations was 862000.0 for Q4 2024 at Roivant Sciences, down from 804000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 3905000.0 in Q4 2023 and bottomed at 862000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | - |
| 3 | BeOne Medicines | 473.13 Bn | 468.34 Bn | 1.35 Bn | - |
| 4 | Vertex Pharmaceuticals | 123.67 Bn | 116.43 Bn | 2.59 Bn | - |
| 5 | Regeneron Pharmaceuticals | 71.57 Bn | 62.81 Bn | 3.31 Bn | - |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | - |
| 7 | Argenx Se | 54.61 Bn | 49.42 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 37.99 Bn | 34.98 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.09 Bn | 36.09 Bn | - | - |
| 10 | Roivant Sciences | 23.44 Bn | 23.44 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -862,000.00 |
| Sep 30, 2024 | 804,000.00 |
| Jun 30, 2024 | 692,000.00 |
| Dec 31, 2023 | 3.91 Mn |
| Sep 30, 2023 | 521,000.00 |